Immusoft Corporation is a biotechnology company focused on developing an autologous cell therapy platform aimed at treating a range of human diseases through its proprietary Immune System Programming (ISP) technology. Founded in 2009 and based in Seattle, Washington, Immusoft specializes in modifying the DNA of a patient's immune cells to create biofactories capable of producing gene-encoded medicines, including essential proteins and enzymes that may be missing or defective. The company's innovative approach involves reprogramming B cells, a type of immune cell, which enables them to manufacture and secrete various antibodies. This process not only provides a potential long-term solution for patients but also positions Immusoft at the forefront of biotechnology in addressing rare and infectious diseases.
Discovery Genomics, Inc. is an early-stage functional genomics company focused on understanding gene functions and validating drug targets to design therapeutic agents. The company utilizes proprietary technologies, including Morphant™ for creating "knock-downs" in Zebrafish, and the Sleeping Beauty Transposon™, both of which are licensed from the University of Minnesota. These technologies enable the study of specific gene functions and have potential applications in gene therapy. The use of Zebrafish as a model system allows for faster and more cost-effective gene discovery compared to traditional vertebrate models. Discovery Genomics aims to leverage this research to develop gene therapies that can correct genetic issues and help alleviate various diseases. As of March 2016, the company operates as a subsidiary of Immusoft Corporation.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.